The Vanguard Group, Inc. > VANGUARD SPECIALIZED FUNDS
VANGUARD HEALTH CARE FUND
$46.28B
Avg Monthly Net Assets
$48.91B
Total Assets
$77.43M
Total Liabilities
$48.84B
Net Assets
VANGUARD HEALTH CARE FUND is a Mutual Fund in VANGUARD SPECIALIZED FUNDS
from The Vanguard Group, Inc.,
based in Pennsylvania,
United States of America.
The fund has two share classes
and monthly net assets of $46.28B.
On September 27th, 2024 it reported 107 holdings, the largest
being Eli Lilly & Co (8.2%), UnitedHealth Group Inc (7.5%) and AstraZeneca PLC (5.6%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Ticker | Monthly Returns (2 years) |
|---|---|---|---|
| Admiral Shares | C000008008 | VGHAX | |
| Investor Shares | C000008007 | VGHCX |
Holdings
From latest NPORT-P, filed September 27th, 2024 for period ending July 31st, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| ABBOTT LABS (Abbott Laboratories) | Long | Equity-common | US | $700M | 7M | 1.43 |
| ACADIA HEALTHCAR (Acadia Healthcare Co Inc) | Long | Equity-common | US | $307M | 5M | 0.63 |
| AGILENT TECH INC (Agilent Technologies Inc) | Long | Equity-common | US | $484M | 3M | 0.99 |
| AGILON HEALTH IN (agilon health Inc) | Long | Equity-common | US | $239M | 35M | 0.49 |
| AKERO THERAPEUTI (Akero Therapeutics Inc) | Long | Equity-common | US | $67M | 3M | 0.14 |
| ALIGN TECHNOLOGY (Align Technology Inc) | Long | Equity-common | US | $335M | 1M | 0.69 |
| ALKERMES PLC | Long | Equity-common | US | $235M | 9M | 0.48 |
| ALNYLAM PHARMACE (Alnylam Pharmaceuticals Inc) | Long | Equity-common | US | $1B | 5M | 2.40 |
| AMICUS THERAPEUT (Amicus Therapeutics Inc) | Long | Equity-common | US | $168M | 16M | 0.34 |
| APELLIS PHARMACE (Apellis Pharmaceuticals Inc) | Long | Equity-common | US | $400M | 10M | 0.82 |
| APOGEE THERAPEUT (Apogee Therapeutics Inc) | Long | Equity-common | US | $76M | 2M | 0.16 |
| ARGENX SE | Long | Equity-common | BE | $821M | 2M | 1.68 |
| ASCENDIS PHA-ADR (Ascendis Pharma A/S) | Long | Equity-common | US | $269M | 2M | 0.55 |
| ASTELLAS PHARMA (Astellas Pharma Inc) | Long | Equity-common | JP | $329M | 28M | 0.67 |
| ASTRAZENECA PLC | Long | Equity-common | GB | $3B | 17M | 5.64 |
| AUTOLUS THERAPEU (Autolus Therapeutics PLC) | Long | Equity-common | US | $89M | 19M | 0.18 |
| AVIDITY BIOSCIEN (Avidity Biosciences Inc) | Long | Equity-common | US | $58M | 1M | 0.12 |
| BIOGEN INC | Long | Equity-common | US | $972M | 5M | 1.99 |
| BLUEPRINT MEDICI (Blueprint Medicines Corp) | Long | Equity-common | US | $164M | 2M | 0.34 |
| BOA-MTG TRIPARTY REPO (Bank of America Securities, LLC) | Long | Repurchase agreement | US | $53M | – | 0.11 |
| BOSTON SCIENTIFC (Boston Scientific Corp) | Long | Equity-common | US | $1B | 14M | 2.08 |
| BZW TRIPARTY TREASURY (Barclays Capital Inc.) | Long | Repurchase agreement | US | $108M | – | 0.22 |
| CELLDEX THERAPEU (Celldex Therapeutics Inc) | Long | Equity-common | US | $145M | 4M | 0.30 |
| CENCORA INC | Long | Equity-common | US | $489M | 2M | 1.00 |
| CENTENE CORP | Long | Equity-common | US | $662M | 9M | 1.36 |
| CHUGAI PHARMA CO (Chugai Pharmaceutical Co Ltd) | Long | Equity-common | JP | $766M | 18M | 1.57 |
| CONVATEC GROUP P (ConvaTec Group PLC) | Long | Equity-common | GB | $28M | 9M | 0.06 |
| CREDIT AGRICOLE TRIPARTY TSY | Long | Repurchase agreement | US | $83M | – | 0.17 |
| CRINETICS PHARMA (Crinetics Pharmaceuticals Inc) | Long | Equity-common | US | $51M | 960K | 0.10 |
| CYTOKINETICS INC | Long | Equity-common | US | $240M | 4M | 0.49 |
| DAIICHI SANKYO (Daiichi Sankyo Co Ltd) | Long | Equity-common | JP | $2B | 37M | 3.08 |
| DANAHER CORP | Long | Equity-common | US | $1B | 5M | 2.80 |
| DENALI THERAPEUT (Denali Therapeutics Inc) | Long | Equity-common | US | $214M | 9M | 0.44 |
| DEXCOM (Dexcom Inc) | Long | Equity-common | US | $198M | 3M | 0.40 |
| DIASORIN SPA | Long | Equity-common | IT | $58M | 530K | 0.12 |
| EDWARDS LIFE (Edwards Lifesciences Corp) | Long | Equity-common | US | $713M | 11M | 1.46 |
| EISAI CO LTD | Long | Equity-common | JP | $729M | 19M | 1.49 |
| ELEVANCE HEALTH (Elevance Health Inc) | Long | Equity-common | US | $1B | 2M | 2.44 |
| ELI LILLY & CO | Long | Equity-common | US | $4B | 5M | 8.21 |
| ENCOMPASS HEALTH (Encompass Health Corp) | Long | Equity-common | US | $195M | 2M | 0.40 |
| EVOLENT HEALTH-A (Evolent Health Inc) | Long | Equity-common | US | $134M | 6M | 0.28 |
| EXACT SCIENCES (Exact Sciences Corp) | Long | Equity-common | US | $230M | 5M | 0.47 |
| GALAPAGOS NV | Long | Equity-common | NL | $17M | 624K | 0.03 |
| GALDERMA GROUP A (Galderma Group AG) | Long | Equity-common | CH | $256M | 3M | 0.53 |
| GENMAB A/S | Long | Equity-common | DK | $468M | 2M | 0.96 |
| GENMAB A/S-S ADR | Long | Equity-common | US | $65M | 2M | 0.13 |
| GENUS PLC | Long | Equity-common | GB | $42M | 2M | 0.09 |
| GLAUKOS CORP | Long | Equity-common | US | $25M | 211K | 0.05 |
| GSK PLC | Long | Equity-common | GB | $713M | 37M | 1.46 |
| GUARDANT HEALTH (Guardant Health Inc) | Long | Equity-common | US | $132M | 4M | 0.27 |
| HAPVIDA PARTICIP (Hapvida Participacoes e Investimentos S/A) | Long | Equity-common | BR | $6M | 9M | 0.01 |
| HCA HEALTHCARE I (HCA Healthcare Inc) | Long | Equity-common | US | $721M | 2M | 1.48 |
| HSBC TRIPARTY MTGE (HSBC Bank USA) | Long | Repurchase agreement | US | $62M | – | 0.13 |
| HSBC TRIPARTY TREAS (HSBC Bank USA) | Long | Repurchase agreement | US | $63M | – | 0.13 |
| HUMANA INC | Long | Equity-common | US | $577M | 2M | 1.18 |
| IMMUNOCORE HOLDI (Immunocore Holdings PLC) | Long | Equity-common | US | $153M | 4M | 0.31 |
| INSMED INC | Long | Equity-common | US | $17M | 228K | 0.03 |
| INTUITIVE SURGIC (Intuitive Surgical Inc) | Long | Equity-common | US | $795M | 2M | 1.63 |
| IONIS PHARMACEUT (Ionis Pharmaceuticals Inc) | Long | Equity-common | US | $233M | 5M | 0.48 |
| IQVIA HOLDINGS I (IQVIA Holdings Inc) | Long | Equity-common | US | $263M | 1M | 0.54 |
| JPM TRIPARTY TREAS FICC (JP Morgan Securities LLC) | Long | Repurchase agreement | US | $44M | – | 0.09 |
| KYMERA THERAPEUT (Kymera Therapeutics Inc) | Long | Equity-common | US | $67M | 1M | 0.14 |
| LABCORP HOLDINGS (Labcorp Holdings Inc) | Long | Equity-common | US | $249M | 1M | 0.51 |
| LEGEND BIOT-ADR (Legend Biotech Corp) | Long | Equity-common | US | $107M | 2M | 0.22 |
| MERCK & CO (Merck & Co Inc) | Long | Equity-common | US | $2B | 18M | 4.21 |
| MERUS NV | Long | Equity-common | US | $59M | 1M | 0.12 |
| MODERNA INC | Long | Equity-common | US | $451M | 4M | 0.92 |
| MOLINA HEALTHCAR (Molina Healthcare Inc) | Long | Equity-common | US | $290M | 849K | 0.59 |
| NATIXIS TRIPARTY TR (Natixis SA) | Long | Repurchase agreement | US | $90M | – | 0.19 |
| NOMURA TREAS TRIPARTY (Nomura Securities International, Inc.) | Long | Repurchase agreement | US | $77M | – | 0.16 |
| NOVARTIS AG-REG | Long | Equity-common | CH | $2B | 16M | 3.63 |
| NOVO NORDISK-B (Novo Nordisk A/S) | Long | Equity-common | DK | $2B | 13M | 3.44 |
| OPTION CARE HEAL (Option Care Health Inc) | Long | Equity-common | US | $147M | 5M | 0.30 |
| OTSUKA HOLDINGS (Otsuka Holdings Co Ltd) | Long | Equity-common | JP | $420M | 8M | 0.86 |
| PACS GROUP INC | Long | Equity-common | US | $83M | 2M | 0.17 |
| PARIB TRIPARTY MORTGAGE (BNP Paribas Securities Corp.) | Long | Repurchase agreement | US | $73M | – | 0.15 |
| PARIB TRIPARTY TREASURY (BNP Paribas Securities Corp.) | Long | Repurchase agreement | US | $97M | – | 0.20 |
| PFIZER INC | Long | Equity-common | US | $1B | 42M | 2.60 |
| PRIVIA HEALTH GR (Privia Health Group Inc) | Long | Equity-common | US | $67M | 3M | 0.14 |
| PROTHENA CORP PL (Prothena Corp PLC) | Long | Equity-common | US | $70M | 3M | 0.14 |
| PTC THERAPEUTICS (PTC Therapeutics Inc) | Long | Equity-common | US | $141M | 4M | 0.29 |
| QIAGEN NV | Long | Equity-common | US | $100M | 2M | 0.21 |
| RBC TRIPARTY MTGE (RBC Capital Markets LLC) | Long | Repurchase agreement | US | $69M | – | 0.14 |
| REGENERON PHARM (Regeneron Pharmaceuticals Inc) | Long | Equity-common | US | $534M | 495K | 1.09 |
| REVOLUTION MEDIC (REVOLUTION Medicines Inc) | Long | Equity-common | US | $275M | 6M | 0.56 |
| ROCKET PHARMACEU (Rocket Pharmaceuticals Inc) | Long | Equity-common | US | $157M | 6M | 0.32 |
| SAREPTA THERAPEU (Sarepta Therapeutics Inc) | Long | Equity-common | US | $180M | 1M | 0.37 |
| SCOTIA TRIPARTY TREASURY (Bank of Nova Scotia) | Long | Repurchase agreement | US | $115M | – | 0.24 |
| SHANDONG WEIG-H (Shandong Weigao Group Medical Polymer Co Ltd) | Long | Equity-common | HK | $39M | 77M | 0.08 |
| STEVANATO GROUP (Stevanato Group SpA) | Long | Equity-common | US | $34M | 2M | 0.07 |
| STRUCTURE THERAP (Structure Therapeutics Inc) | Long | Equity-common | US | $151M | 4M | 0.31 |
| STRYKER CORP | Long | Equity-common | US | $615M | 2M | 1.26 |
| SURGERY PARTNERS (Surgery Partners Inc) | Long | Equity-common | US | $110M | 4M | 0.22 |
| SYNDAX PHARMACEU (Syndax Pharmaceuticals Inc) | Long | Equity-common | US | $96M | 4M | 0.20 |
| TECAN GROUP AG-R | Long | Equity-common | CH | $88M | 236K | 0.18 |
| TERUMO CORP | Long | Equity-common | JP | $250M | 14M | 0.51 |
| THERMO FISHER (Thermo Fisher Scientific Inc) | Long | Equity-common | US | $1B | 2M | 2.55 |
| UCB SA | Long | Equity-common | BE | $1B | 7M | 2.34 |
| UNITED THERAPEUT (United Therapeutics Corp) | Long | Equity-common | US | $264M | 843K | 0.54 |
| UNITEDHEALTH GRP (UnitedHealth Group Inc) | Long | Equity-common | US | $4B | 6M | 7.49 |
| Vanguard Market Liquidity Fund (Vanguard Cmt Funds-Vanguard Market Liquidity Fund) | Long | Short-term investment vehicle | US | $90M | 902K | 0.18 |
| VAXCYTE INC | Long | Equity-common | US | $183M | 2M | 0.38 |
| VERTEX PHARM (Vertex Pharmaceuticals Inc) | Long | Equity-common | US | $943M | 2M | 1.93 |
| XENON PHARMACEUT (Xenon Pharmaceuticals Inc) | Long | Equity-common | US | $110M | 3M | 0.22 |
| ZAI LAB LTD | Long | Equity-common | HK | $56M | 30M | 0.12 |
| ZAI LAB LTD-ADR | Long | Equity-common | US | $54M | 3M | 0.11 |
| ZOETIS INC | Long | Equity-common | US | $504M | 3M | 1.03 |
Address
VANGUARD SPECIALIZED FUNDS
100 Vanguard Boulevard
Malvern
Pennsylvania
19355
United States of America
Websites
Directors
F. Joseph Loughrey
Mortimer J. Buckley
David Thomas
Scott C. Malpass
Emerson U. Fullwood
Tara Bunch
Sarah Bloom Raskin
Grant Reid
Deanna Mulligan
Peter F. Volanakis
Lubos Pastor
Mark Loughridge
Andre F. Perold
Transfer Agents
The Vanguard Group, Inc.
Pricing Services
ITG Analytics Inc
JPMorgan Chase Bank
Bloomberg Finance LP
Markit North America INC
Refinitiv US LLC
ICE Data Pricing and Reference Data LLC
Markit Group Limited
Custodians
Deutsche Bank AG
JPMorgan Chase Bank NA
Euroclear
CACEIS Bank Spain SAU
The Hongkong and Shanghai Banking Corporation Limited
J.P. MORGAN SE - LUXEMBOURG BRANCH
JPMorgan Chase Bank NA
FirstRand Bank Limited
Skandinaviska Enskilda Banken AB (publ)
BNP Paribas S.A.
JPMorgan Chase Bank NA
JPMorgan Chase Bank NA
BNP Paribas S.A.
Skandinaviska Enskilda Banken AB (publ)
GCD Denmark
BNP Paribas S.A. - Athens Branch
Royal Bank of Canada
DBS Bank Ltd
JPMorgan Chase Bank NA
JPMorgan Chase Bank NA
JP Morgan SA DTVM
Skandinaviska Enskilda Banken AB (publ)
J.P. MORGAN SE - LUXEMBOURG BRANCH
Banco Nacional de Mexico SA
JP MORGAN SE LUXEMBOURG BRANCH
UniCredit Bank Austria AG
BNP Paribas S.A. - Athens Branch
UniCredit Bank Czech Republic and Slovakia as
Deutsche Bank AG
The Hongkong and Shanghai Banking Corporation Limited
Bank Leumi leIsrael BM
Societe Generale Marocaine de Banques
Mizuho Bank Ltd
J.P. MORGAN SE - LUXEMBOURG BRANCH
Shareholder Servicing Agents
The Vanguard Group, Inc.
Admins
JPMORGAN CHASE BANK, N.A.
THE VANGUARD GROUP, INC.
Brokers
BNP PARIBAS ARBITRAGE
Morgan Stanley & Co. LLC
Merrill Lynch International
Goldman Sachs & Co. LLC
J.P. Morgan Securities LLC
CITIGROUP INC.
Exane
UBS Securities LLC
BofA Securities, Inc.
Mizuho Securities USA Inc